Literature DB >> 23636009

Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring.

R E Schmieder1, L M Ruilope, C Ott, F Mahfoud, M Böhm.   

Abstract

It is well known that 24-h ambulatory blood pressure monitoring (ABPM) provides a more accurate picture of a patient's blood pressure (BP) compared with clinic BP measurement. Twenty-four-hour ABPM better predicts hypertension-related risks such as end-organ damage including left ventricular hypertrophy, cardiovascular (CV) events and mortality. Threshold BP values for hypertension based on 24-h ABPM results have been established, including daytime and night-time averages. Nevertheless, the relationship between 24-h ABPM and clinic BP measurement in patients on antihypertensive therapy, and in particular how each may change in response to antihypertensive therapy, is less clear. This review will provide an overview of current knowledge on the relation between clinic BP and ambulatory BP reductions in clinical trials on antihypertensive therapies. Reduction in CV risk and its correlation with the magnitude of reduction in both clinic and ambulatory BP are explored. The most striking result is that reduction in clinic BP and ambulatory BP do not correspond in a 1:1 fashion, that is, smaller changes in 24-h ABPM correspond to significantly larger changes in clinic BP.

Entities:  

Mesh:

Year:  2013        PMID: 23636009     DOI: 10.1038/jhh.2013.39

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  Renal denervation--implications for chronic kidney disease.

Authors:  Roland Veelken; Roland E Schmieder
Journal:  Nat Rev Nephrol       Date:  2014-04-15       Impact factor: 28.314

2.  Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring.

Authors:  J Rick Turner; Eoin O'Brien
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-09-19       Impact factor: 3.738

3.  Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.

Authors:  Alfonso Perez; Charlie Cao
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-15       Impact factor: 3.738

4.  Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry.

Authors:  Iris Kistner; Uwe Zeymer; Ralf Dechend; Ina Hagedorn; Thomas Riemer; Peter Bramlage; David Pittrow; Jochen Senges; Roland E Schmieder
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-04-20       Impact factor: 3.738

5.  The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.

Authors:  Alfonso Perez; Charlie Cao
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-25       Impact factor: 3.738

6.  Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease.

Authors:  Aleksander Prejbisz; Jacek Kądziela; Jacek Lewandowski; Elżbieta Florczak; Ewa Zylińska; Mariusz Kłopotowski; Adam Witkowski; Andrzej Januszewicz
Journal:  Clin Res Cardiol       Date:  2013-12-10       Impact factor: 5.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.